Biome Australia Limited
Biome Australia Limited (BIO.AX) Stock Competitors & Peer Comparison
See (BIO.AX) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| BIO.AX | A$0.55 | -3.54% | 120.2M | -54.50 | -A$0.01 | N/A |
| CSL.AX | A$271.11 | -0.33% | 131.3B | 32.62 | A$8.31 | +1.57% |
| TLX.AX | A$20.68 | +0.68% | 7B | 147.71 | A$0.14 | N/A |
| MSB.AX | A$2.45 | -1.61% | 3.1B | -12.25 | -A$0.20 | N/A |
| NEU.AX | A$16.63 | -0.42% | 2.1B | 15.26 | A$1.09 | N/A |
| CU6.AX | A$4.33 | +0.00% | 1.4B | -27.06 | -A$0.16 | N/A |
| PYC.AX | A$1.27 | +1.20% | 743.7M | -11.59 | -A$0.11 | N/A |
| OPT.AX | A$0.60 | +0.00% | 738.8M | -1.40 | -A$0.43 | N/A |
| CUV.AX | A$12.83 | +2.56% | 643.1M | 16.66 | A$0.77 | +0.39% |
| IMM.AX | A$0.27 | -1.85% | 389M | -8.83 | -A$0.03 | N/A |
Stock Comparison
BIO.AX vs CSL.AX Comparison July 2025
BIO.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO.AX stands at 120.2M. In comparison, CSL.AX has a market cap of 131.3B. Regarding current trading prices, BIO.AX is priced at A$0.55, while CSL.AX trades at A$271.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO.AX currently has a P/E ratio of -54.50, whereas CSL.AX's P/E ratio is 32.62. In terms of profitability, BIO.AX's ROE is +0.08%, compared to CSL.AX's ROE of +0.15%. Regarding short-term risk, BIO.AX is more volatile compared to CSL.AX. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.AX.Check CSL.AX's competition here
BIO.AX vs TLX.AX Comparison July 2025
BIO.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO.AX stands at 120.2M. In comparison, TLX.AX has a market cap of 7B. Regarding current trading prices, BIO.AX is priced at A$0.55, while TLX.AX trades at A$20.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO.AX currently has a P/E ratio of -54.50, whereas TLX.AX's P/E ratio is 147.71. In terms of profitability, BIO.AX's ROE is +0.08%, compared to TLX.AX's ROE of +0.06%. Regarding short-term risk, BIO.AX is more volatile compared to TLX.AX. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.AX.Check TLX.AX's competition here
BIO.AX vs MSB.AX Comparison July 2025
BIO.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO.AX stands at 120.2M. In comparison, MSB.AX has a market cap of 3.1B. Regarding current trading prices, BIO.AX is priced at A$0.55, while MSB.AX trades at A$2.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO.AX currently has a P/E ratio of -54.50, whereas MSB.AX's P/E ratio is -12.25. In terms of profitability, BIO.AX's ROE is +0.08%, compared to MSB.AX's ROE of -0.22%. Regarding short-term risk, BIO.AX is more volatile compared to MSB.AX. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.AX.Check MSB.AX's competition here
BIO.AX vs NEU.AX Comparison July 2025
BIO.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO.AX stands at 120.2M. In comparison, NEU.AX has a market cap of 2.1B. Regarding current trading prices, BIO.AX is priced at A$0.55, while NEU.AX trades at A$16.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO.AX currently has a P/E ratio of -54.50, whereas NEU.AX's P/E ratio is 15.26. In terms of profitability, BIO.AX's ROE is +0.08%, compared to NEU.AX's ROE of +0.49%. Regarding short-term risk, BIO.AX is more volatile compared to NEU.AX. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.AX.Check NEU.AX's competition here
BIO.AX vs CU6.AX Comparison July 2025
BIO.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO.AX stands at 120.2M. In comparison, CU6.AX has a market cap of 1.4B. Regarding current trading prices, BIO.AX is priced at A$0.55, while CU6.AX trades at A$4.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO.AX currently has a P/E ratio of -54.50, whereas CU6.AX's P/E ratio is -27.06. In terms of profitability, BIO.AX's ROE is +0.08%, compared to CU6.AX's ROE of -0.36%. Regarding short-term risk, BIO.AX is more volatile compared to CU6.AX. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.AX.Check CU6.AX's competition here
BIO.AX vs PYC.AX Comparison July 2025
BIO.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO.AX stands at 120.2M. In comparison, PYC.AX has a market cap of 743.7M. Regarding current trading prices, BIO.AX is priced at A$0.55, while PYC.AX trades at A$1.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO.AX currently has a P/E ratio of -54.50, whereas PYC.AX's P/E ratio is -11.59. In terms of profitability, BIO.AX's ROE is +0.08%, compared to PYC.AX's ROE of -0.71%. Regarding short-term risk, BIO.AX is more volatile compared to PYC.AX. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.AX.Check PYC.AX's competition here
BIO.AX vs OPT.AX Comparison July 2025
BIO.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO.AX stands at 120.2M. In comparison, OPT.AX has a market cap of 738.8M. Regarding current trading prices, BIO.AX is priced at A$0.55, while OPT.AX trades at A$0.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO.AX currently has a P/E ratio of -54.50, whereas OPT.AX's P/E ratio is -1.40. In terms of profitability, BIO.AX's ROE is +0.08%, compared to OPT.AX's ROE of +5.43%. Regarding short-term risk, BIO.AX is more volatile compared to OPT.AX. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.AX.Check OPT.AX's competition here
BIO.AX vs CUV.AX Comparison July 2025
BIO.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO.AX stands at 120.2M. In comparison, CUV.AX has a market cap of 643.1M. Regarding current trading prices, BIO.AX is priced at A$0.55, while CUV.AX trades at A$12.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO.AX currently has a P/E ratio of -54.50, whereas CUV.AX's P/E ratio is 16.66. In terms of profitability, BIO.AX's ROE is +0.08%, compared to CUV.AX's ROE of +0.18%. Regarding short-term risk, BIO.AX is more volatile compared to CUV.AX. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.AX.Check CUV.AX's competition here
BIO.AX vs IMM.AX Comparison July 2025
BIO.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO.AX stands at 120.2M. In comparison, IMM.AX has a market cap of 389M. Regarding current trading prices, BIO.AX is priced at A$0.55, while IMM.AX trades at A$0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO.AX currently has a P/E ratio of -54.50, whereas IMM.AX's P/E ratio is -8.83. In terms of profitability, BIO.AX's ROE is +0.08%, compared to IMM.AX's ROE of -0.24%. Regarding short-term risk, BIO.AX is more volatile compared to IMM.AX. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.AX.Check IMM.AX's competition here
BIO.AX vs OCC.AX Comparison July 2025
BIO.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO.AX stands at 120.2M. In comparison, OCC.AX has a market cap of 317M. Regarding current trading prices, BIO.AX is priced at A$0.55, while OCC.AX trades at A$1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO.AX currently has a P/E ratio of -54.50, whereas OCC.AX's P/E ratio is -64.75. In terms of profitability, BIO.AX's ROE is +0.08%, compared to OCC.AX's ROE of -0.27%. Regarding short-term risk, BIO.AX is more volatile compared to OCC.AX. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.AX.Check OCC.AX's competition here
BIO.AX vs BOT.AX Comparison July 2025
BIO.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO.AX stands at 120.2M. In comparison, BOT.AX has a market cap of 304M. Regarding current trading prices, BIO.AX is priced at A$0.55, while BOT.AX trades at A$0.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO.AX currently has a P/E ratio of -54.50, whereas BOT.AX's P/E ratio is -7.75. In terms of profitability, BIO.AX's ROE is +0.08%, compared to BOT.AX's ROE of -0.39%. Regarding short-term risk, BIO.AX is more volatile compared to BOT.AX. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.AX.Check BOT.AX's competition here
BIO.AX vs DXB.AX Comparison July 2025
BIO.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO.AX stands at 120.2M. In comparison, DXB.AX has a market cap of 285.1M. Regarding current trading prices, BIO.AX is priced at A$0.55, while DXB.AX trades at A$0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO.AX currently has a P/E ratio of -54.50, whereas DXB.AX's P/E ratio is -11.87. In terms of profitability, BIO.AX's ROE is +0.08%, compared to DXB.AX's ROE of -1.84%. Regarding short-term risk, BIO.AX is more volatile compared to DXB.AX. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.AX.Check DXB.AX's competition here
BIO.AX vs RAC.AX Comparison July 2025
BIO.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO.AX stands at 120.2M. In comparison, RAC.AX has a market cap of 204.1M. Regarding current trading prices, BIO.AX is priced at A$0.55, while RAC.AX trades at A$1.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO.AX currently has a P/E ratio of -54.50, whereas RAC.AX's P/E ratio is -23.50. In terms of profitability, BIO.AX's ROE is +0.08%, compared to RAC.AX's ROE of -0.39%. Regarding short-term risk, BIO.AX is more volatile compared to RAC.AX. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.AX.Check RAC.AX's competition here
BIO.AX vs PAR.AX Comparison July 2025
BIO.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO.AX stands at 120.2M. In comparison, PAR.AX has a market cap of 153M. Regarding current trading prices, BIO.AX is priced at A$0.55, while PAR.AX trades at A$0.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO.AX currently has a P/E ratio of -54.50, whereas PAR.AX's P/E ratio is -7.70. In terms of profitability, BIO.AX's ROE is +0.08%, compared to PAR.AX's ROE of -0.54%. Regarding short-term risk, BIO.AX is more volatile compared to PAR.AX. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.AX.Check PAR.AX's competition here
BIO.AX vs ATH.AX Comparison July 2025
BIO.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO.AX stands at 120.2M. In comparison, ATH.AX has a market cap of 128.9M. Regarding current trading prices, BIO.AX is priced at A$0.55, while ATH.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO.AX currently has a P/E ratio of -54.50, whereas ATH.AX's P/E ratio is -1.40. In terms of profitability, BIO.AX's ROE is +0.08%, compared to ATH.AX's ROE of -1.83%. Regarding short-term risk, BIO.AX is more volatile compared to ATH.AX. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.AX.Check ATH.AX's competition here
BIO.AX vs ALA.AX Comparison July 2025
BIO.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO.AX stands at 120.2M. In comparison, ALA.AX has a market cap of 117.7M. Regarding current trading prices, BIO.AX is priced at A$0.55, while ALA.AX trades at A$0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO.AX currently has a P/E ratio of -54.50, whereas ALA.AX's P/E ratio is -9.90. In terms of profitability, BIO.AX's ROE is +0.08%, compared to ALA.AX's ROE of -0.55%. Regarding short-term risk, BIO.AX is more volatile compared to ALA.AX. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.AX.Check ALA.AX's competition here
BIO.AX vs PAA.AX Comparison July 2025
BIO.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO.AX stands at 120.2M. In comparison, PAA.AX has a market cap of 111.9M. Regarding current trading prices, BIO.AX is priced at A$0.55, while PAA.AX trades at A$0.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO.AX currently has a P/E ratio of -54.50, whereas PAA.AX's P/E ratio is -11.50. In terms of profitability, BIO.AX's ROE is +0.08%, compared to PAA.AX's ROE of -0.87%. Regarding short-term risk, BIO.AX is more volatile compared to PAA.AX. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.AX.Check PAA.AX's competition here
BIO.AX vs RCE.AX Comparison July 2025
BIO.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO.AX stands at 120.2M. In comparison, RCE.AX has a market cap of 111.3M. Regarding current trading prices, BIO.AX is priced at A$0.55, while RCE.AX trades at A$0.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO.AX currently has a P/E ratio of -54.50, whereas RCE.AX's P/E ratio is -4.28. In terms of profitability, BIO.AX's ROE is +0.08%, compared to RCE.AX's ROE of +2.47%. Regarding short-term risk, BIO.AX is more volatile compared to RCE.AX. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.AX.Check RCE.AX's competition here
BIO.AX vs EZZ.AX Comparison July 2025
BIO.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO.AX stands at 120.2M. In comparison, EZZ.AX has a market cap of 101.9M. Regarding current trading prices, BIO.AX is priced at A$0.55, while EZZ.AX trades at A$2.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO.AX currently has a P/E ratio of -54.50, whereas EZZ.AX's P/E ratio is 10.29. In terms of profitability, BIO.AX's ROE is +0.08%, compared to EZZ.AX's ROE of +0.40%. Regarding short-term risk, BIO.AX is more volatile compared to EZZ.AX. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.AX.Check EZZ.AX's competition here
BIO.AX vs ATX.AX Comparison July 2025
BIO.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO.AX stands at 120.2M. In comparison, ATX.AX has a market cap of 93.5M. Regarding current trading prices, BIO.AX is priced at A$0.55, while ATX.AX trades at A$0.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO.AX currently has a P/E ratio of -54.50, whereas ATX.AX's P/E ratio is -12.00. In terms of profitability, BIO.AX's ROE is +0.08%, compared to ATX.AX's ROE of -0.51%. Regarding short-term risk, BIO.AX is more volatile compared to ATX.AX. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.AX.Check ATX.AX's competition here
BIO.AX vs AGN.AX Comparison July 2025
BIO.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO.AX stands at 120.2M. In comparison, AGN.AX has a market cap of 87.4M. Regarding current trading prices, BIO.AX is priced at A$0.55, while AGN.AX trades at A$0.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO.AX currently has a P/E ratio of -54.50, whereas AGN.AX's P/E ratio is -13.60. In terms of profitability, BIO.AX's ROE is +0.08%, compared to AGN.AX's ROE of -0.39%. Regarding short-term risk, BIO.AX is more volatile compared to AGN.AX. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.AX.Check AGN.AX's competition here
BIO.AX vs IMU.AX Comparison July 2025
BIO.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO.AX stands at 120.2M. In comparison, IMU.AX has a market cap of 80.8M. Regarding current trading prices, BIO.AX is priced at A$0.55, while IMU.AX trades at A$0.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO.AX currently has a P/E ratio of -54.50, whereas IMU.AX's P/E ratio is -0.47. In terms of profitability, BIO.AX's ROE is +0.08%, compared to IMU.AX's ROE of -1.42%. Regarding short-term risk, BIO.AX is more volatile compared to IMU.AX. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.AX.Check IMU.AX's competition here
BIO.AX vs NSB.AX Comparison July 2025
BIO.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO.AX stands at 120.2M. In comparison, NSB.AX has a market cap of 79.8M. Regarding current trading prices, BIO.AX is priced at A$0.55, while NSB.AX trades at A$0.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO.AX currently has a P/E ratio of -54.50, whereas NSB.AX's P/E ratio is 24.00. In terms of profitability, BIO.AX's ROE is +0.08%, compared to NSB.AX's ROE of +0.23%. Regarding short-term risk, BIO.AX is more volatile compared to NSB.AX. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.AX.Check NSB.AX's competition here
BIO.AX vs ACW.AX Comparison July 2025
BIO.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO.AX stands at 120.2M. In comparison, ACW.AX has a market cap of 79.4M. Regarding current trading prices, BIO.AX is priced at A$0.55, while ACW.AX trades at A$0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO.AX currently has a P/E ratio of -54.50, whereas ACW.AX's P/E ratio is -2.50. In terms of profitability, BIO.AX's ROE is +0.08%, compared to ACW.AX's ROE of -0.44%. Regarding short-term risk, BIO.AX is more volatile compared to ACW.AX. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.AX.Check ACW.AX's competition here
BIO.AX vs NYR.AX Comparison July 2025
BIO.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO.AX stands at 120.2M. In comparison, NYR.AX has a market cap of 77.8M. Regarding current trading prices, BIO.AX is priced at A$0.55, while NYR.AX trades at A$0.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO.AX currently has a P/E ratio of -54.50, whereas NYR.AX's P/E ratio is -18.50. In terms of profitability, BIO.AX's ROE is +0.08%, compared to NYR.AX's ROE of -0.73%. Regarding short-term risk, BIO.AX is more volatile compared to NYR.AX. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.AX.Check NYR.AX's competition here
BIO.AX vs PIQ.AX Comparison July 2025
BIO.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO.AX stands at 120.2M. In comparison, PIQ.AX has a market cap of 60.6M. Regarding current trading prices, BIO.AX is priced at A$0.55, while PIQ.AX trades at A$0.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO.AX currently has a P/E ratio of -54.50, whereas PIQ.AX's P/E ratio is -6.17. In terms of profitability, BIO.AX's ROE is +0.08%, compared to PIQ.AX's ROE of -0.96%. Regarding short-term risk, BIO.AX is more volatile compared to PIQ.AX. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.AX.Check PIQ.AX's competition here
BIO.AX vs RAD.AX Comparison July 2025
BIO.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO.AX stands at 120.2M. In comparison, RAD.AX has a market cap of 52M. Regarding current trading prices, BIO.AX is priced at A$0.55, while RAD.AX trades at A$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO.AX currently has a P/E ratio of -54.50, whereas RAD.AX's P/E ratio is -0.37. In terms of profitability, BIO.AX's ROE is +0.08%, compared to RAD.AX's ROE of -1.03%. Regarding short-term risk, BIO.AX is less volatile compared to RAD.AX. This indicates potentially lower risk in terms of short-term price fluctuations for BIO.AX.Check RAD.AX's competition here
BIO.AX vs ADO.AX Comparison July 2025
BIO.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO.AX stands at 120.2M. In comparison, ADO.AX has a market cap of 51.4M. Regarding current trading prices, BIO.AX is priced at A$0.55, while ADO.AX trades at A$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO.AX currently has a P/E ratio of -54.50, whereas ADO.AX's P/E ratio is -1.70. In terms of profitability, BIO.AX's ROE is +0.08%, compared to ADO.AX's ROE of -1.34%. Regarding short-term risk, BIO.AX is less volatile compared to ADO.AX. This indicates potentially lower risk in terms of short-term price fluctuations for BIO.AX.Check ADO.AX's competition here
BIO.AX vs ILA.AX Comparison July 2025
BIO.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO.AX stands at 120.2M. In comparison, ILA.AX has a market cap of 42M. Regarding current trading prices, BIO.AX is priced at A$0.55, while ILA.AX trades at A$0.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO.AX currently has a P/E ratio of -54.50, whereas ILA.AX's P/E ratio is -5.67. In terms of profitability, BIO.AX's ROE is +0.08%, compared to ILA.AX's ROE of -1.20%. Regarding short-term risk, BIO.AX is less volatile compared to ILA.AX. This indicates potentially lower risk in terms of short-term price fluctuations for BIO.AX.Check ILA.AX's competition here
BIO.AX vs SPL.AX Comparison July 2025
BIO.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO.AX stands at 120.2M. In comparison, SPL.AX has a market cap of 39.7M. Regarding current trading prices, BIO.AX is priced at A$0.55, while SPL.AX trades at A$0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO.AX currently has a P/E ratio of -54.50, whereas SPL.AX's P/E ratio is -3.17. In terms of profitability, BIO.AX's ROE is +0.08%, compared to SPL.AX's ROE of -0.49%. Regarding short-term risk, BIO.AX is more volatile compared to SPL.AX. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.AX.Check SPL.AX's competition here
BIO.AX vs CYP.AX Comparison July 2025
BIO.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO.AX stands at 120.2M. In comparison, CYP.AX has a market cap of 38.4M. Regarding current trading prices, BIO.AX is priced at A$0.55, while CYP.AX trades at A$0.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO.AX currently has a P/E ratio of -54.50, whereas CYP.AX's P/E ratio is -3.40. In terms of profitability, BIO.AX's ROE is +0.08%, compared to CYP.AX's ROE of -0.95%. Regarding short-term risk, BIO.AX is more volatile compared to CYP.AX. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.AX.Check CYP.AX's competition here
BIO.AX vs NOX.AX Comparison July 2025
BIO.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO.AX stands at 120.2M. In comparison, NOX.AX has a market cap of 36.5M. Regarding current trading prices, BIO.AX is priced at A$0.55, while NOX.AX trades at A$0.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO.AX currently has a P/E ratio of -54.50, whereas NOX.AX's P/E ratio is -12.50. In terms of profitability, BIO.AX's ROE is +0.08%, compared to NOX.AX's ROE of -0.47%. Regarding short-term risk, BIO.AX is less volatile compared to NOX.AX. This indicates potentially lower risk in terms of short-term price fluctuations for BIO.AX.Check NOX.AX's competition here
BIO.AX vs PTX.AX Comparison July 2025
BIO.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO.AX stands at 120.2M. In comparison, PTX.AX has a market cap of 36.2M. Regarding current trading prices, BIO.AX is priced at A$0.55, while PTX.AX trades at A$0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO.AX currently has a P/E ratio of -54.50, whereas PTX.AX's P/E ratio is -4.50. In terms of profitability, BIO.AX's ROE is +0.08%, compared to PTX.AX's ROE of -0.42%. Regarding short-term risk, BIO.AX is more volatile compared to PTX.AX. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.AX.Check PTX.AX's competition here
BIO.AX vs LCT.AX Comparison July 2025
BIO.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO.AX stands at 120.2M. In comparison, LCT.AX has a market cap of 24.5M. Regarding current trading prices, BIO.AX is priced at A$0.55, while LCT.AX trades at A$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO.AX currently has a P/E ratio of -54.50, whereas LCT.AX's P/E ratio is N/A. In terms of profitability, BIO.AX's ROE is +0.08%, compared to LCT.AX's ROE of -0.54%. Regarding short-term risk, BIO.AX is more volatile compared to LCT.AX. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.AX.Check LCT.AX's competition here
BIO.AX vs NC6.AX Comparison July 2025
BIO.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO.AX stands at 120.2M. In comparison, NC6.AX has a market cap of 24.4M. Regarding current trading prices, BIO.AX is priced at A$0.55, while NC6.AX trades at A$0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO.AX currently has a P/E ratio of -54.50, whereas NC6.AX's P/E ratio is -8.00. In terms of profitability, BIO.AX's ROE is +0.08%, compared to NC6.AX's ROE of +3.42%. Regarding short-term risk, BIO.AX is more volatile compared to NC6.AX. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.AX.Check NC6.AX's competition here
BIO.AX vs BTC.AX Comparison July 2025
BIO.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO.AX stands at 120.2M. In comparison, BTC.AX has a market cap of 20.5M. Regarding current trading prices, BIO.AX is priced at A$0.55, while BTC.AX trades at A$0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO.AX currently has a P/E ratio of -54.50, whereas BTC.AX's P/E ratio is 6.30. In terms of profitability, BIO.AX's ROE is +0.08%, compared to BTC.AX's ROE of +0.58%. Regarding short-term risk, BIO.AX is more volatile compared to BTC.AX. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.AX.Check BTC.AX's competition here
BIO.AX vs KZA.AX Comparison July 2025
BIO.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO.AX stands at 120.2M. In comparison, KZA.AX has a market cap of 18.9M. Regarding current trading prices, BIO.AX is priced at A$0.55, while KZA.AX trades at A$0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO.AX currently has a P/E ratio of -54.50, whereas KZA.AX's P/E ratio is -0.73. In terms of profitability, BIO.AX's ROE is +0.08%, compared to KZA.AX's ROE of -1.33%. Regarding short-term risk, BIO.AX is less volatile compared to KZA.AX. This indicates potentially lower risk in terms of short-term price fluctuations for BIO.AX.Check KZA.AX's competition here
BIO.AX vs IMC.AX Comparison July 2025
BIO.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO.AX stands at 120.2M. In comparison, IMC.AX has a market cap of 17.2M. Regarding current trading prices, BIO.AX is priced at A$0.55, while IMC.AX trades at A$0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO.AX currently has a P/E ratio of -54.50, whereas IMC.AX's P/E ratio is -2.27. In terms of profitability, BIO.AX's ROE is +0.08%, compared to IMC.AX's ROE of -0.64%. Regarding short-term risk, BIO.AX is more volatile compared to IMC.AX. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.AX.Check IMC.AX's competition here
BIO.AX vs AVE.AX Comparison July 2025
BIO.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO.AX stands at 120.2M. In comparison, AVE.AX has a market cap of 15.9M. Regarding current trading prices, BIO.AX is priced at A$0.55, while AVE.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO.AX currently has a P/E ratio of -54.50, whereas AVE.AX's P/E ratio is N/A. In terms of profitability, BIO.AX's ROE is +0.08%, compared to AVE.AX's ROE of -0.83%. Regarding short-term risk, BIO.AX is less volatile compared to AVE.AX. This indicates potentially lower risk in terms of short-term price fluctuations for BIO.AX.Check AVE.AX's competition here
BIO.AX vs MDC.AX Comparison July 2025
BIO.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO.AX stands at 120.2M. In comparison, MDC.AX has a market cap of 15.1M. Regarding current trading prices, BIO.AX is priced at A$0.55, while MDC.AX trades at A$6.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO.AX currently has a P/E ratio of -54.50, whereas MDC.AX's P/E ratio is -0.01. In terms of profitability, BIO.AX's ROE is +0.08%, compared to MDC.AX's ROE of +2.75%. Regarding short-term risk, BIO.AX is more volatile compared to MDC.AX. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.AX.Check MDC.AX's competition here
BIO.AX vs TRP.AX Comparison July 2025
BIO.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO.AX stands at 120.2M. In comparison, TRP.AX has a market cap of 14.5M. Regarding current trading prices, BIO.AX is priced at A$0.55, while TRP.AX trades at A$0.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO.AX currently has a P/E ratio of -54.50, whereas TRP.AX's P/E ratio is -3.43. In terms of profitability, BIO.AX's ROE is +0.08%, compared to TRP.AX's ROE of -0.26%. Regarding short-term risk, BIO.AX is more volatile compared to TRP.AX. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.AX.Check TRP.AX's competition here
BIO.AX vs BNO.AX Comparison July 2025
BIO.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO.AX stands at 120.2M. In comparison, BNO.AX has a market cap of 13.2M. Regarding current trading prices, BIO.AX is priced at A$0.55, while BNO.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO.AX currently has a P/E ratio of -54.50, whereas BNO.AX's P/E ratio is -0.45. In terms of profitability, BIO.AX's ROE is +0.08%, compared to BNO.AX's ROE of -0.90%. Regarding short-term risk, BIO.AX is less volatile compared to BNO.AX. This indicates potentially lower risk in terms of short-term price fluctuations for BIO.AX.Check BNO.AX's competition here
BIO.AX vs CHM.AX Comparison July 2025
BIO.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO.AX stands at 120.2M. In comparison, CHM.AX has a market cap of 13M. Regarding current trading prices, BIO.AX is priced at A$0.55, while CHM.AX trades at A$0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO.AX currently has a P/E ratio of -54.50, whereas CHM.AX's P/E ratio is -0.20. In terms of profitability, BIO.AX's ROE is +0.08%, compared to CHM.AX's ROE of -4.24%. Regarding short-term risk, BIO.AX is less volatile compared to CHM.AX. This indicates potentially lower risk in terms of short-term price fluctuations for BIO.AX.Check CHM.AX's competition here
BIO.AX vs MEM.AX Comparison July 2025
BIO.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO.AX stands at 120.2M. In comparison, MEM.AX has a market cap of 8.9M. Regarding current trading prices, BIO.AX is priced at A$0.55, while MEM.AX trades at A$0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO.AX currently has a P/E ratio of -54.50, whereas MEM.AX's P/E ratio is N/A. In terms of profitability, BIO.AX's ROE is +0.08%, compared to MEM.AX's ROE of -0.79%. Regarding short-term risk, BIO.AX is less volatile compared to MEM.AX. This indicates potentially lower risk in terms of short-term price fluctuations for BIO.AX.Check MEM.AX's competition here
BIO.AX vs ACR.AX Comparison July 2025
BIO.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO.AX stands at 120.2M. In comparison, ACR.AX has a market cap of 7.4M. Regarding current trading prices, BIO.AX is priced at A$0.55, while ACR.AX trades at A$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO.AX currently has a P/E ratio of -54.50, whereas ACR.AX's P/E ratio is -0.90. In terms of profitability, BIO.AX's ROE is +0.08%, compared to ACR.AX's ROE of -1.79%. Regarding short-term risk, BIO.AX is more volatile compared to ACR.AX. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.AX.Check ACR.AX's competition here
BIO.AX vs IXC.AX Comparison July 2025
BIO.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO.AX stands at 120.2M. In comparison, IXC.AX has a market cap of 6.4M. Regarding current trading prices, BIO.AX is priced at A$0.55, while IXC.AX trades at A$0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO.AX currently has a P/E ratio of -54.50, whereas IXC.AX's P/E ratio is -4.25. In terms of profitability, BIO.AX's ROE is +0.08%, compared to IXC.AX's ROE of +0.02%. Regarding short-term risk, BIO.AX is less volatile compared to IXC.AX. This indicates potentially lower risk in terms of short-term price fluctuations for BIO.AX.Check IXC.AX's competition here
BIO.AX vs BGT.AX Comparison July 2025
BIO.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO.AX stands at 120.2M. In comparison, BGT.AX has a market cap of 5.8M. Regarding current trading prices, BIO.AX is priced at A$0.55, while BGT.AX trades at A$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO.AX currently has a P/E ratio of -54.50, whereas BGT.AX's P/E ratio is -1.90. In terms of profitability, BIO.AX's ROE is +0.08%, compared to BGT.AX's ROE of -1.15%. Regarding short-term risk, BIO.AX is more volatile compared to BGT.AX. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.AX.Check BGT.AX's competition here
BIO.AX vs ZLD.AX Comparison July 2025
BIO.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO.AX stands at 120.2M. In comparison, ZLD.AX has a market cap of 4.9M. Regarding current trading prices, BIO.AX is priced at A$0.55, while ZLD.AX trades at A$0.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO.AX currently has a P/E ratio of -54.50, whereas ZLD.AX's P/E ratio is -0.98. In terms of profitability, BIO.AX's ROE is +0.08%, compared to ZLD.AX's ROE of +0.75%. Regarding short-term risk, BIO.AX is more volatile compared to ZLD.AX. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.AX.Check ZLD.AX's competition here
BIO.AX vs PAB.AX Comparison July 2025
BIO.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO.AX stands at 120.2M. In comparison, PAB.AX has a market cap of 4.7M. Regarding current trading prices, BIO.AX is priced at A$0.55, while PAB.AX trades at A$0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO.AX currently has a P/E ratio of -54.50, whereas PAB.AX's P/E ratio is N/A. In terms of profitability, BIO.AX's ROE is +0.08%, compared to PAB.AX's ROE of -1.14%. Regarding short-term risk, BIO.AX is more volatile compared to PAB.AX. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.AX.Check PAB.AX's competition here
BIO.AX vs RGS.AX Comparison July 2025
BIO.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO.AX stands at 120.2M. In comparison, RGS.AX has a market cap of 3.7M. Regarding current trading prices, BIO.AX is priced at A$0.55, while RGS.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO.AX currently has a P/E ratio of -54.50, whereas RGS.AX's P/E ratio is -1.20. In terms of profitability, BIO.AX's ROE is +0.08%, compared to RGS.AX's ROE of +4.56%. Regarding short-term risk, BIO.AX is less volatile compared to RGS.AX. This indicates potentially lower risk in terms of short-term price fluctuations for BIO.AX.Check RGS.AX's competition here
BIO.AX vs VBS.AX Comparison July 2025
BIO.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO.AX stands at 120.2M. In comparison, VBS.AX has a market cap of 3.2M. Regarding current trading prices, BIO.AX is priced at A$0.55, while VBS.AX trades at A$0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO.AX currently has a P/E ratio of -54.50, whereas VBS.AX's P/E ratio is -1.50. In terms of profitability, BIO.AX's ROE is +0.08%, compared to VBS.AX's ROE of -2.39%. Regarding short-term risk, BIO.AX is more volatile compared to VBS.AX. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.AX.Check VBS.AX's competition here
BIO.AX vs BIT.AX Comparison July 2025
BIO.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO.AX stands at 120.2M. In comparison, BIT.AX has a market cap of 2.7M. Regarding current trading prices, BIO.AX is priced at A$0.55, while BIT.AX trades at A$0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO.AX currently has a P/E ratio of -54.50, whereas BIT.AX's P/E ratio is -0.20. In terms of profitability, BIO.AX's ROE is +0.08%, compared to BIT.AX's ROE of -13.17%. Regarding short-term risk, BIO.AX is more volatile compared to BIT.AX. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.AX.Check BIT.AX's competition here
BIO.AX vs 1AD.AX Comparison July 2025
BIO.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO.AX stands at 120.2M. In comparison, 1AD.AX has a market cap of 2.2M. Regarding current trading prices, BIO.AX is priced at A$0.55, while 1AD.AX trades at A$0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO.AX currently has a P/E ratio of -54.50, whereas 1AD.AX's P/E ratio is -0.20. In terms of profitability, BIO.AX's ROE is +0.08%, compared to 1AD.AX's ROE of -4.64%. Regarding short-term risk, BIO.AX is more volatile compared to 1AD.AX. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.AX.Check 1AD.AX's competition here
BIO.AX vs HXL.AX Comparison July 2025
BIO.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO.AX stands at 120.2M. In comparison, HXL.AX has a market cap of 2.2M. Regarding current trading prices, BIO.AX is priced at A$0.55, while HXL.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO.AX currently has a P/E ratio of -54.50, whereas HXL.AX's P/E ratio is -1.30. In terms of profitability, BIO.AX's ROE is +0.08%, compared to HXL.AX's ROE of -0.53%. Regarding short-term risk, BIO.AX is more volatile compared to HXL.AX. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.AX.Check HXL.AX's competition here
BIO.AX vs EX1.AX Comparison July 2025
BIO.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO.AX stands at 120.2M. In comparison, EX1.AX has a market cap of 1.9M. Regarding current trading prices, BIO.AX is priced at A$0.55, while EX1.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO.AX currently has a P/E ratio of -54.50, whereas EX1.AX's P/E ratio is -0.12. In terms of profitability, BIO.AX's ROE is +0.08%, compared to EX1.AX's ROE of -1.10%. Regarding short-term risk, BIO.AX is more volatile compared to EX1.AX. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.AX.Check EX1.AX's competition here
BIO.AX vs ANR.AX Comparison July 2025
BIO.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO.AX stands at 120.2M. In comparison, ANR.AX has a market cap of 1.5M. Regarding current trading prices, BIO.AX is priced at A$0.55, while ANR.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO.AX currently has a P/E ratio of -54.50, whereas ANR.AX's P/E ratio is -0.70. In terms of profitability, BIO.AX's ROE is +0.08%, compared to ANR.AX's ROE of -1.42%. Regarding short-term risk, BIO.AX is more volatile compared to ANR.AX. This indicates potentially higher risk in terms of short-term price fluctuations for BIO.AX.Check ANR.AX's competition here